Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of California, San Francisco, San Francisco, CA.
Pancreas. 2019 Aug;48(7):888-893. doi: 10.1097/MPA.0000000000001350.
Recurrent pancreatitis is considered a rare manifestation of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction; this case series highlights that pancreatitis can be a presenting symptoms of cystic fibrosis (CF) or a CFTR-related disorder (CFTR-RD).
Retrospective review of patients younger than 30 years diagnosed as having acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP) and subsequently diagnosed as having CF or CFTR-RD.
Among 18 patients, median time from diagnosis of ARP/CP to diagnosis of CF was 0.4 years (range, 0-33 years). Eight were classified as having CF by elevated sweat chloride testing (SCT). Five had intermediate SCT (30-59 mmol/L) with 2 pathogenic mutations. Five had CFTR-RD with intermediate SCT and 0 to 1 pathogenic mutations. Eight patients (44%) had exocrine pancreatic insufficiency, and pancreatic fluid collections were more common in this group. Based on the CFTR mutation, 6 patients were eligible for CFTR potentiator therapy, although none received it during the study period. Nine of the 18 had ≥1 other likely CF manifestations, including sinusitis (33%), nasal polyps (11%), pneumonia (22%), and gallbladder disease (22%).
Cystic fibrosis or CFTR-RD can present as ARP/CP. Complete diagnostic testing for CFTR-RD in patients with ARP/CP will broaden treatment options and help to identify comorbid illness.
复发性胰腺炎被认为是囊性纤维化跨膜电导调节因子(CFTR)功能障碍的罕见表现;本病例系列强调,胰腺炎可能是囊性纤维化(CF)或 CFTR 相关疾病(CFTR-RD)的首发症状。
回顾性分析了年龄小于 30 岁的急性复发性胰腺炎(ARP)或慢性胰腺炎(CP)患者,这些患者随后被诊断为 CF 或 CFTR-RD。
在 18 名患者中,从 ARP/CP 诊断到 CF 诊断的中位时间为 0.4 年(范围,0-33 年)。8 例通过升高的汗液氯测试(SCT)被归类为 CF。5 例 SCT 为中间值(30-59mmol/L),有 2 个致病性突变。5 例 CFTR-RD 伴有中间 SCT 和 0 至 1 个致病性突变。8 例(44%)有外分泌胰腺功能不全,该组胰腺液体积聚更为常见。根据 CFTR 突变,有 6 名患者有资格接受 CFTR 增强剂治疗,尽管在研究期间没有接受治疗。18 名患者中有 9 名(44%)有≥1 种其他可能的 CF 表现,包括鼻窦炎(33%)、鼻息肉(11%)、肺炎(22%)和胆囊疾病(22%)。
CF 或 CFTR-RD 可表现为 ARP/CP。对 ARP/CP 患者进行 CFTR-RD 的全面诊断性检测将扩大治疗选择,并有助于识别合并症。